%0 Review
%T Safety of drugs used for the treatment of migraine during pregnancy: a narrative review.
%A Spiteri JA
%A Camilleri G
%A Piccinni C
%A Sultana J
%J Expert Rev Clin Pharmacol
%V 16
%N 3
%D Mar 2023
%M 36803196
%F 4.108
%R 10.1080/17512433.2023.2181157
%X UNASSIGNED: Migraine is common in females of childbearing age and negatively impacts quality of life. The majority of those with migraine who become pregnant see an improvement in their condition but not all do. Providing evidence-based recommendations for the pharmacological management of migraine in pregnancy is challenging.
UNASSIGNED: This narrative review provides an update on the safety of drugs used for migraine in pregnancy. National and international guidelines on the management of episodic migraine in adults were used to select the drugs of relevance to pregnant women. The final list of drugs was chosen by a pain specialist who categorized them according to drug class and use in acute management or prevention. PubMed was searched from inception to 31st July 2022 for evidence on drug safety.
UNASSIGNED: Obtaining high-quality drug safety data in pregnant migraineurs is difficult not least because exposing a fetus to research-related risks is often considered unethical. There is reliance on observational studies which often group drugs together and lack specificities pertinent to drug prescribing like timing, dosing and duration. Improved statistical tools, study designs and the creation of international collaborative frameworks are ways to advance knowledge on drug safety in pregnancy.